Because it is uncommon, exact prevalence numbers are difficult to obtain, but fungal meningitis accounts for < 1 % of all meningitis cases in the United States. Of those, Candida species are responsible for roughly 10–15 % of fungal meningitis episodes, translating to an estimated 100–200 cases per year nationwide (CDC, 2022).

The disease typically affects people with weakened immune systems, such as those receiving chemotherapy, organ‑transplant recipients, patients with advanced HIV/AIDS, and neonates in intensive‑care units. Healthy adults rarely develop Candida meningitis.

Symptoms

Symptoms often develop slowly over days to weeks and can mimic bacterial meningitis, making early recognition challenging. Common manifestations include:

• Headache – persistent, often described as “worst ever.”
• Fever – usually low‑grade (37.5–38.5 °C) but can be higher.
• Neck stiffness – pain or reduced range of motion when trying to touch the chin to the chest.
• Photophobia – discomfort when looking at bright lights.
• Nausea or vomiting – may be early signs of increased intracranial pressure.
• Altered mental status – confusion, lethargy, or difficulty concentrating.
• Seizures – especially in immunocompromised patients.
• Focal neurological deficits – weakness, numbness, or speech problems.
• Auditory or visual changes – ringing in the ears, blurred vision.
• Skin lesions – sometimes a concurrent candidemia presents with red, painful nodules (candidal septic emboli).

In newborns and infants, symptoms may be nonspecific: irritability, poor feeding, bulging fontanelle, and a fever without a clear source.

Causes and Risk Factors

Primary cause

The infection begins when Candida yeast enters the bloodstream (candidemia) and crosses the blood‑brain barrier, colonizing the meninges. Direct inoculation during neurosurgical procedures or spinal taps is possible but uncommon.

Key risk factors

• Severe immunosuppression – HIV/AIDS (CD4 <200 cells/µL), chemotherapy, long‑term corticosteroids, biologic agents.
• Broad‑spectrum antibiotic use – disrupts normal flora, facilitating over‑growth of Candida.
• Central venous catheters or intravascular devices – a frequent source of bloodstream infection.
• Neonatal intensive‑care unit (NICU) stay – especially premature infants with indwelling catheters.
• Organ transplantation – especially liver and kidney transplants.
• Diabetes mellitus – high blood sugar impairs neutrophil function.
• Prior abdominal surgery or gastrointestinal perforation – allows translocation of Candida from the gut.

Diagnosis

Because signs overlap with bacterial meningitis, laboratory confirmation is essential.

Initial evaluation

• Clinical assessment – history, physical exam (meningeal signs), and assessment of immune status.
• Neuroimaging – CT or MRI before lumbar puncture if there is concern for raised intracranial pressure or mass effect.

Laboratory tests

1. Lumbar puncture (CSF analysis)
   • Opening pressure: often elevated.
   • Cell count: moderate pleocytosis with a predominance of lymphocytes (but neutrophils can be present early).
   • Glucose: low (often <40 mg/dL) relative to serum glucose.
   • Protein: elevated.
   • Microscopy: budding yeast cells may be seen with special stains (Grocott’s methenamine silver, India ink).
   • Culture: gold standard – grows Candida in 48–72 h.
   • Antigen testing: β‑D‑glucan in CSF can support fungal infection.
2. Blood cultures – positive in up to 70 % of cases, confirming candidemia.
3. Serum β‑D‑glucan – a non‑specific marker of invasive fungal infection; values >80 pg/mL raise suspicion.
4. Molecular methods (PCR) – increasingly used for rapid detection of Candida DNA in CSF.

Diagnostic criteria (CDC)

Definite Candida meningitis requires isolation of Candida species from CSF (or a sterile site) plus compatible clinical findings. Probable disease may be diagnosed when CSF findings are suggestive and there is evidence of candidemia without another source.

Treatment Options

Management involves antifungal therapy, control of the underlying predisposing condition, and sometimes surgical intervention.

First‑line antifungal regimens

• Amphotericin B (lipid formulation) + flucytosine – recommended initial therapy for ≥2 weeks, followed by oral azole consolidation. Dosage: 5 mg/kg/day IV amphotericin B (liposomal) + flucytosine 100 mg/kg/day divided q6h.
• Echinocandins (caspofungin, micafungin, anidulafungin) – increasingly used as initial therapy when amphotericin B is contraindicated (renal failure, severe infusion reactions). Typical dose: caspofungin 70 mg loading then 50 mg daily.

Step‑down/maintenance therapy

• Fluconazole – oral or IV 400–800 mg daily for 6–12 weeks, depending on clinical response and immune status.
• In azole‑resistant strains (e.g., C. glabrata, C. krusei), voriconazole or **posaconazole** may be used.

Adjunctive measures

• Removal of infected intravascular catheters or foreign bodies.
• Optimization of glycemic control in diabetics.
• Reduction or cessation of immunosuppressive drugs when feasible.
• Management of intracranial pressure (e.g., head elevation, osmotic therapy, ventriculostomy) if hydrocephalus develops.

Duration of therapy

At least 6 weeks of antifungal treatment is typical for immunocompromised hosts; longer courses (up to 12 weeks) may be needed for relapsing disease or when CNS lesions persist on imaging.

Living with Yeast Meningitis (Candida meningitis)

Surviving Candida meningitis often means long‑term follow‑up and lifestyle adjustments.

• Medication adherence – never skip doses; use a pill organizer or set alarms.
• Regular follow‑up labs – liver and kidney function tests every 1–2 weeks during IV therapy, then monthly.
• Imaging surveillance – MRI brain at the end of therapy to confirm resolution of meningeal enhancement.
• Vaccinations – keep up to date with influenza, pneumococcal, and COVID‑19 vaccines; they reduce secondary infections.
• Infection‑control hygiene – frequent hand washing, careful care of any indwelling lines, and avoiding exposure to environments where fungal spores are abundant (e.g., construction sites).
• Nutrition – balanced diet rich in protein, vitamins A, C, D and zinc to support immune recovery.
• Psychological support – chronic illness can cause anxiety or depression; consider counseling or support groups.

Prevention

Because the primary driver is candidemia, preventing bloodstream infection is key.

• Strict aseptic technique for line insertion and maintenance.
• Limit unnecessary broad‑spectrum antibiotics – use antimicrobial stewardship principles.
• Control blood glucose – target HbA1c < 7 % in diabetics.
• Prophylactic antifungals – recommended for high‑risk groups (e.g., hematopoietic stem‑cell transplant patients) per IDSA guidelines.
• Vaccinate against viral infections that can cause immune dysregulation.
• Early removal of central lines once they are no longer essential.

Complications

If not promptly treated, Candida meningitis can lead to serious, sometimes irreversible complications:

• Hydrocephalus – blockage of CSF flow requiring shunt placement.
• Brain abscesses or fungal granulomas – may need neurosurgical drainage.
• Seizure disorders – can become chronic.
• Stroke – due to vasculitis or embolic phenomena.
• Persistent neurocognitive deficits – memory, concentration, and motor skills may be affected.
• Relapse or disseminated candidiasis – infection can spread to eyes (endophthalmitis), heart (endocarditis), or bones.
• Mortality – reported 30‑45 % in immunocompromised adults, higher in neonates (up to 60 %).

When to Seek Emergency Care

References

• Centers for Disease Control and Prevention. “Fungal Meningitis.” 2022. https://www.cdc.gov/fungal/diseases/meningitis.html
• Infectious Diseases Society of America. “Clinical Practice Guidelines for the Management of Candidiasis.” Clin Infect Dis. 2020;71(3):e57‑e230.
• Mayo Clinic. “Fungal meningitis.” Updated 2023. https://www.mayoclinic.org/…
• National Institutes of Health. “Candida Infections – Diagnosis and Treatment.” 2021. https://www.ncbi.nlm.nih.gov/books/NBK426/
• World Health Organization. “Antimicrobial Resistance: Global Report on Surveillance.” 2022.
• Cleveland Clinic. “Candida Meningitis.” 2023. https://my.clevelandclinic.org/…